Oruka Therapeutics Raises $700M at $72.50 After 64% Skin-Clearance Readout
NEW YORK, May 1 —
Oruka Therapeutics priced an upsized $700M stock offering at $72.50 a share, hours after Phase 2a data showed ORKA-001 cleared skin in 64% of plaque psoriasis patients at Week 16.
- $700M offering priced at $72.50, upsized from a $500M launch, sold under the company's existing shelf
- Stock at $64.17, trading below the deal price after a record-high spike on the trial readout
- UBS raised its price target to $100 from $75, maintaining a Buy rating
What Actually Happened
Oruka turned a clinical readout into a balance sheet event in roughly a day. The company expanded a $500M marketed offering to $700M because demand was there, which is the only reason a biotech ever upsizes. The hook is durability: 64% skin clearance at Week 16 is competitive with the IL-23 incumbents, and Oruka's pitch is once-yearly dosing rather than the every-eight-weeks regimen patients live with today. A drug that works as well, less often, in a market the size of psoriasis is a category claim worth the cash raise.
The Catch
The stock is at $64.17. The deal cleared at $72.50. UBS sees $100. Two of those three numbers can't all be true at once, and the market is voting with the lowest one. That's the dilution overhang in action: the float just got bigger, and shares are settling to where the new buyers got in, not where pre-deal holders thought it was worth. The Phase 2a result is a single 16-week look at moderate-to-severe patients. Phase 2b/3 has to replicate it, and biologics history is full of Week 16 winners that lose in longer trials against established comparators.
Bottom Line
This is a more investable Oruka than it was a week ago. The $700M raise pushes runway through the readouts that actually decide the franchise, and management didn't have to give the company away to get it. The setup favors growth investors who can sit through the dilution math and wait for Phase 2b/3 trial initiation, which is now the next thing that matters. Watch for updated cash runway guidance: that's the number that tells you whether $700M is two trials of dry powder or three.
No Basis Report exists yet for ORKA. Generate one at /stock/orka to see the full model.
Basis Report does not hold positions in securities discussed. This is not investment advice.